Germline variation in TP53 regulatory network genes associates with breast cancer survival and treatment outcome
✍ Scribed by Jamshidi, Maral; Schmidt, Marjanka K.; Dörk, Thilo; Garcia-Closas, Montserrat; Heikkinen, Tuomas; Cornelissen, Sten; van den Broek, Alexandra J.; Schürmann, Peter; Meyer, Andreas; Park-Simon, Tjoung-Won; Figueroa, Jonine; Sherman, Mark; Lissowska, Jolanta; Keong, Garrett Teoh Hor; Irwanto, Astrid; Laakso, Marko; Hautaniemi, Sampsa; Aittomäki, Kristiina; Blomqvist, Carl; Liu, Jianjun; Nevanlinna, Heli
- Book ID
- 124062276
- Publisher
- John Wiley and Sons
- Year
- 2012
- Tongue
- French
- Weight
- 448 KB
- Volume
- 132
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
The tumor suppressor TP53 pathway plays a crucial role in preventing carcinogenesis through its ability to impose cell cycle arrest and apoptosis following DNA damage and oncogene activation. MDM2 is a key negative regulator of the TP53 pathway and is overexpressed in many cancers as oncoprotein. We
We examined the association between mutation of the p53 gene and survival in a large cohort of breast cancer patients. Using a rapid, non-isotopic single-strand conformation polymorphism (SSCP) method we screened for mutations in exons 4-10 of the p53 gene in 375 primary breast cancers from patients